PYXSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Pyxis Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.76+0.08 (+4.76%)
Close on Oct 19, 2026
- Market cap
- $112.63M
- P/E (TTM)
- –
- Dividend yield
- –
Pyxis Oncology, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | % of revenue | YoY |
|---|---|---|---|---|
| Sale of Royalty Rights | $11.04M | $8.00M | 79.7% | +38.0% |
| Milestone Revenue | $2.82M | $0 | 20.3% | – |
| Royalty Revenues | $0 | $8.15M | 0.0% | -100.0% |
| Royalty revenue and sale of royalty rights | – | $16.15M | – | – |
By region
From the segment and revenue-disaggregation notes of Pyxis Oncology's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.